KYMERA THERAPEUTICS, INC. Operating Expenses
KYMERA THERAPEUTICS, INC. (KYMR) reported Operating Expenses of $140.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $140.61M, a 46.42% increase year-over-year.
- KYMERA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $118.52M, a 22.78% increase year-over-year.
- KYMERA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $100.77M, a 14.31% increase year-over-year.
- KYMERA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $95.28M, a 25.60% increase year-over-year.
- KYMERA THERAPEUTICS, INC. operating expenses for fiscal 2025 was $388.61M, a 25.88% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. operating expenses for fiscal 2024 was $308.71M, a 26.46% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. operating expenses for fiscal 2023 was $244.12M, a 17.32% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. operating expenses for fiscal 2022 was $208.08M, a 20.03% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $140.61M 10-Q · filed 2026-08-05 | $259.13M 10-Q · filed 2026-08-05 | $359.89M derived: sum of 3 quarters · filed 2026-08-05 | $455.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $118.52M 10-Q · filed 2026-04-30 | $219.28M derived: sum of 2 quarters · filed 2026-04-30 | $314.57M derived: sum of 3 quarters · filed 2026-04-30 | $410.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $100.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $196.05M derived: sum of 2 quarters · filed 2026-02-26 | $292.08M derived: sum of 3 quarters · filed 2026-08-05 | $388.61M 10-K · filed 2026-02-26 |
| 2025-09-30 | $95.28M 10-Q · filed 2025-11-04 | $191.32M derived: sum of 2 quarters · filed 2026-08-05 | $287.84M 10-Q · filed 2025-11-04 | $375.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $96.03M 10-Q · filed 2026-08-05 | $192.56M 10-Q · filed 2026-08-05 | $280.71M derived: sum of 3 quarters · filed 2026-08-05 | $356.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $96.53M 10-Q · filed 2026-04-30 | $184.68M derived: sum of 2 quarters · filed 2026-04-30 | $260.54M derived: sum of 3 quarters · filed 2026-04-30 | $337.12M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $88.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $164.01M derived: sum of 2 quarters · filed 2026-02-26 | $240.59M derived: sum of 3 quarters · filed 2026-02-26 | $308.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | $75.86M 10-Q · filed 2025-11-04 | $152.44M derived: sum of 2 quarters · filed 2025-11-04 | $220.56M 10-Q · filed 2025-11-04 | $287.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $76.58M 10-Q · filed 2025-08-11 | $144.69M 10-Q · filed 2025-08-11 | $211.89M derived: sum of 3 quarters · filed 2026-02-26 | $274.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $68.12M 10-Q · filed 2025-05-09 | $135.31M derived: sum of 2 quarters · filed 2026-02-26 | $197.55M derived: sum of 3 quarters · filed 2026-02-26 | $257.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $67.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $129.43M derived: sum of 2 quarters · filed 2026-02-26 | $189.33M derived: sum of 3 quarters · filed 2026-02-26 | $244.12M 10-K · filed 2026-02-26 |
| 2023-09-30 | $62.24M 10-Q · filed 2024-10-31 | $122.13M derived: sum of 2 quarters · filed 2024-10-31 | $176.93M 10-Q · filed 2024-10-31 | $231.69M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $59.90M 10-Q · filed 2024-08-07 | $114.69M 10-Q · filed 2024-08-07 | $169.46M derived: sum of 3 quarters · filed 2025-02-27 | $223.89M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $54.79M 10-Q · filed 2024-05-02 | $109.56M derived: sum of 2 quarters · filed 2025-02-27 | $163.99M derived: sum of 3 quarters · filed 2025-02-27 | $216.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $54.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $109.20M derived: sum of 2 quarters · filed 2025-02-27 | $161.53M derived: sum of 3 quarters · filed 2025-02-27 | $208.08M 10-K · filed 2025-02-27 |
| 2022-09-30 | $54.43M 10-Q · filed 2023-11-02 | $106.76M derived: sum of 2 quarters · filed 2023-11-02 | $153.31M 10-Q · filed 2023-11-02 | $202.58M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $52.32M 10-Q · filed 2023-08-03 | $98.88M 10-Q · filed 2023-08-03 | $148.15M derived: sum of 3 quarters · filed 2024-02-22 | $197.12M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $46.55M 10-Q · filed 2023-05-04 | $95.82M derived: sum of 2 quarters · filed 2024-02-22 | $144.80M derived: sum of 3 quarters · filed 2024-02-22 | $188.05M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $49.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $98.24M derived: sum of 2 quarters · filed 2024-02-22 | $141.49M derived: sum of 3 quarters · filed 2024-02-22 | $173.36M 10-K · filed 2024-02-22 |
| 2021-09-30 | $48.97M 10-Q · filed 2022-11-03 | $92.22M derived: sum of 2 quarters · filed 2022-11-03 | $124.09M 10-Q · filed 2022-11-03 | $149.66M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $43.25M 10-Q · filed 2022-08-09 | $75.12M 10-Q · filed 2022-08-09 | $100.69M derived: sum of 3 quarters · filed 2023-02-23 | $123.30M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $31.87M 10-Q · filed 2022-05-03 | $57.44M derived: sum of 2 quarters · filed 2023-02-23 | $80.05M derived: sum of 3 quarters · filed 2023-02-23 | $97.53M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $25.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $48.18M derived: sum of 2 quarters · filed 2023-02-23 | $65.66M derived: sum of 3 quarters · filed 2023-02-23 | $80.34M 10-K · filed 2023-02-23 |
| 2020-09-30 | $22.62M 10-Q · filed 2021-11-10 | $40.10M derived: sum of 2 quarters · filed 2021-11-10 | $54.77M 10-Q · filed 2021-11-10 | $68.39M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $17.48M 10-Q · filed 2021-08-06 | $32.16M 10-Q · filed 2021-08-06 | $45.77M derived: sum of 3 quarters · filed 2022-02-24 | $58.58M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $14.68M 10-Q · filed 2021-05-06 | $28.29M derived: sum of 2 quarters · filed 2022-02-24 | $41.10M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $13.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $26.43M derived: sum of 2 quarters · filed 2022-02-24 | $45.14M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $12.81M 10-Q · filed 2020-11-05 | $31.52M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |